Internal Medicine, Hematology & Oncology · Beverly Hills, CA
NPI
1700839362
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
8900 Wilshire Blvd
Beverly Hills, CA, 90211
Phone (310) 432-8900
Groups this clinician bills Medicare through
Medicare paid, 2024
$492K
29,799 services
Medicare patients, 2024
191
Average age 71
Drug cost, 2024
$1.5M
1,011 prescriptions
Company payments, 2025
$85K
From 50 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Linnea I Chap was code J0897 (injection, denosumab, 1 mg), 4,860 times for 32 patients. In total Linnea I Chap billed 29,799 services in 71 codes, and Medicare paid $492K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-03-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 4,860 | 32 | $18.67 | $91K |
| 85025 Blood Count | Office | 456 | 166 | $7.61 | $3,470 |
| 80053 Clinical Chemistry | Office | 454 | 166 | $10.35 | $4,699 |
| 86300 Immunoassay | Office | 387 | 152 | $20.39 | $7,891 |
| 36415 Venipuncture Blood Collection | Office | 354 | 154 | $8.65 | $3,062 |
| 99214 Office E&M - Established | Office | 331 | 157 | $99.50 | $33K |
| 96372 Injection Administration | Office | 99 | 41 | $12.01 | $1,189 |
| 99213 Office E&M - Established | Office | 62 | 52 | $66.28 | $4,109 |
| 96413 Chemotherapy Administration | Office | 59 | 11 | $117.98 | $6,961 |
| 99215 Office E&M - Established | Office | 43 | 25 | $143.23 | $6,159 |
| 96365 Intravenous Infusion, Hydration | Office | 29 | 12 | $57.41 | $1,665 |
| 82378 Clinical Chemistry | Office | 27 | 18 | $18.58 | $502 |
| 99205 Office E&M - New | Office | 13 | 13 | $189.19 | $2,460 |
By year: 2022 $319K for 36,015 services; 2023 $434K for 49,993 services; 2024 $492K for 29,799 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 456 | 166 | $7.61 | $3,470 |
| 80053 Clinical Chemistry | 454 | 166 | $10.35 | $4,699 |
| 86300 Immunoassay | 387 | 152 | $20.39 | $7,891 |
| 36415 Venipuncture Blood Collection | 354 | 154 | $8.65 | $3,062 |
| 82378 Clinical Chemistry | 27 | 18 | $18.58 | $502 |
Medicare prescription drug claims, 2024
In 2024, the drug Linnea I Chap prescribed most often to Medicare patients was Letrozole, with 167 prescriptions and refills. In total Linnea I Chap wrote 1,011 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 167 | 329 | 36 | $2,902 |
| Alendronate Sodium Generic | 118 | 165 | 19 | $311 |
| Anastrozole Generic | 95 | 157 | 24 | $1,005 |
| Exemestane Generic | 89 | 161 | 18 | $15K |
| Gabapentin Generic | 52 | 63 | 11 | $1,059 |
| Kisqali Ribociclib Succinate | 39 | 39 | Under 11 | $584K |
| Prolia Denosumab | 28 | 168 | 23 | $43K |
| Potassium Chloride Generic | 20 | 42 | Under 11 | $788 |
| Duloxetine Hcl Generic | 17 | 17 | Under 11 | $120 |
| Zolpidem Tartrate Generic | 17 | 17 | Under 11 | $71.53 |
| Xgeva Denosumab | 17 | 17 | Under 11 | $55K |
| Phesgo Pertuzumab-Trastuzumab-Hy-Zzxf | 16 | 16 | Under 11 | $132K |
| Tamoxifen Citrate Generic | 16 | 31 | Under 11 | $211 |
| Lapatinib Lapatinib Ditosylate | 15 | 15 | Under 11 | $76K |
| Dexamethasone Sodium Phosphate Generic | 14 | 14 | Under 11 | $22.19 |
Brand drugs: 179 claims; generic drugs: 832 claims; opioid claims: 17.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Linnea I Chap $85K ($85K in general payments such as food, travel and fees) from 50 companies. The largest payer was Pfizer Inc. with $34K.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 25 | $34K |
| Daiichi Sankyo Inc. 4568.T | 25 | $14K |
| AstraZeneca Pharmaceuticals LP AZN | 33 | $13K |
| Gilead Sciences, Inc. GILD | 16 | $8,576 |
| Stemline Therapeutics Inc. | 9 | $6,564 |
| Novartis Pharmaceuticals Corporation NVS | 21 | $4,220 |
| Eli Lilly and Company LLY | 1 | $1,250 |
| Abbvie Inc. ABBV | 6 | $154 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 6 | $150 |
| Janssen Biotech, Inc. JNJ | 8 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.